Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study on Ambulatory Intraocular Pressure and Blood Pressure Monitoring in Glaucoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01912599
Recruitment Status : Completed
First Posted : July 31, 2013
Results First Posted : June 17, 2016
Last Update Posted : June 17, 2016
Sponsor:
Collaborator:
Sensimed AG
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill

Brief Summary:

Purpose: To study the feasibility of a larger study by determining the tolerability of measuring blood pressure (BP) and intraocular pressure (IOP) over 24 hours in an ambulatory fashion with automatic devices.

Participants: 20 patients with moderate to severe normal tension glaucoma and 20 non-glaucomatous patients.

Procedures (methods): Both BP and IOP will be measured automatically in each participant in an ambulatory fashion during a 24-hour period. BP will be monitored using an appropriately sized cuff Oscar 2 (Suntech Medical, Morrisville, NC), which will be placed by a person trained in ambulatory BP monitoring devices. The device will be set up to automatically inflate every 30 minutes during the day and every hour during the night to measure and record the BP. IOP will be measured using Sensimed Triggerfish contact lens (Sensimed AG, Lausanne, Switzerland); the measurements will be taken and recorded every 10 minutes. The contact lens will be inserted by eye doctors (investigators). Both monitoring devices will be removed the following day.


Condition or disease Intervention/treatment Phase
Normal-Tension Glaucoma Device: Sensimed Triggerfish Device: Blood Pressure Not Applicable

Detailed Description:

Chart review will be performed to select potential glaucoma participants. These potential participants will be invited to participate in the study, either by phone or face-to-face during scheduled visits.

Control participants will be invited from a registry that contains names of prior research participants who have agreed to be contacted about future studies (participants have worn ambulatory blood pressure monitor or ABPM in the past).

Invited persons who agree to participate in the study will be scheduled for a screening visit at the eye clinic, during which they will learn more about the study. On the day of the screening visit, they will be provided with detailed information about the study, after which they will decide whether or not to participate. If they agree, they will sign the consent form. The screening visit will then be conducted by the research personnel and will take place at the eye clinic in a designated closed office and will include measurement of visual acuity, assessment of the anterior and posterior segments of the eye, measurement of IOP by Goldmann applanation tonometry. If after the screening exam it is determined that they do not qualify for the study, they will be told why they are being excluded. Healthy controls as well as glaucomatous patients not on treatment will be fitted with the BP and IOP monitoring devices. Those who are on glaucoma medication will be asked to stop their medication starting the day following the screening visit for the duration detailed in the inclusion criteria, and be given an appointment for the for IOP and BP measurement. On the appointment day, they will be fitted the BP and IOP monitoring devices. The BP monitor will be set up to take the measurements automatically every 30 min during the day and every hour at night until the next morning. The IOP monitor will take measurements every 10 minutes during the 24-hour period. Both devices are computerized and record all the measurements and reading times. Patients will be required to return to the clinic the next morning for removal of the devices, after which there will be no further visits.

  1. This study will provide for the first time information on the safety, tolerance, and acceptability of the two devices used together. It will also provide preliminary information on the reasons why people may drop out of the study, and information about the relationship between IOP, BP, and OPP in patients with normal tension glaucoma and in healthy controls.
  2. IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period. Measurements are taken every 10 min for a total duration of 1 min. The results obtained are presented in an arbitrary unit and not mm Hg. In this study, tonometry will be performed using radiofrequency waves at 27 MHz from the external antenna, which is embedded in the patch applied around the patient's eye.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Pilot Study on Ambulatory Intraocular Pressure and Blood Pressure Monitoring in Glaucoma
Study Start Date : July 2013
Actual Primary Completion Date : July 2014
Actual Study Completion Date : July 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Arm Intervention/treatment
Active Comparator: Non-Glaucomatous
Patients with no history of glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
Device: Sensimed Triggerfish
IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.

Device: Blood Pressure
Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.

Active Comparator: Glaucoma
Patients that are currently being treated for moderate to severe normal-tension glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
Device: Sensimed Triggerfish
IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.

Device: Blood Pressure
Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.




Primary Outcome Measures :
  1. Arterial Pressure [ Time Frame: 24 Hours ]
    The blood pressure value shown in the table is the mean of all measurements taken over the 24 hour period, so it is the average value.

  2. Intraocular Pressure [ Time Frame: 24 Hours ]
    The IOP provided is the average of all 144 measurements taken during the 24 hour period.

  3. Mean Perfusion Pressure [ Time Frame: 24 Hours ]
    The value shown in the table is the mean of all measurements taken over the 24 hour period, so it is the average value.

  4. Diastolic Pressure [ Time Frame: 24 Hours ]
    The value shown in the table is the mean of all measurements taken over the 24 hour period, so it is the average value.

  5. Systolic Pressure [ Time Frame: 24 Hours ]
    The value shown in the table is the mean of all measurements taken over the 24 hour period, so it is the average value.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 1) Patients with normal tension glaucoma

    • Age minimum: 18 years
    • Willingness to participate in the study and to sign the informed consent form.
    • Willingness to complete a screening visit and a study visit, both at the UNC eye clinic.
    • Established diagnosis of untreated or medically treated normal tension glaucoma irrespective of blood pressure level. Those currently treated with topical drops will only be included in the study if they accept to stop their medication according to the following plan: 1) Those treated with Alphagan, Combigan or Cosopt (or Trusopt, Azopt, Diamox, Neptazane) will be asked to stop their medication for a week, do the study for 24 hours, and then resume with their medication. 2) Those treated with Timolol or Xalatan (or Travatan, Lumigan) will be asked to stop their drops for one month, do the study for 24 hours, and then resume the medication regimen. The reason for this is that the study aims at investigating the relationship between blood pressure and intraocular pressure in untreated patients either for glaucoma or high blood pressure. The difference in duration of time during which patients will be off their glaucoma medication depends on the time it takes to clear the drug in the system. In both cases, glaucoma medication will be stopped from the day following the screening visit.

      2) Non-glaucomatous healthy controls

    • Age minimum: 18 years
    • Willingness to participate in the study and to sign a consent form
    • Willingness to complete a screening visit at UNC eye clinic
    • Normal eye examination

Exclusion Criteria:

  • 1) Patients with normal tension glaucoma

    • Age less than 18 years or greater than 80 years.
    • Patients with high intraocular pressure (> 21 mmHg).
    • Patients who have had any type of glaucoma surgery in the past.
    • Non-glaucomatous optic neuropathy.
    • Intraocular surgery within the last 3 months.
    • Patients with uveitis
    • Ocular abnormalities preventing measurement of intraocular pressure by applanation
    • Patients on medication to treat high blood pressure will not be included in the study.
    • Patients with hyperthyroidism
    • Patients on medication that may raise blood pressure: i.e. systemic or topical steroids taken for 3 or more years for other chronic conditions; cholesterol lowering medications, specifically cholestyramine (Prevalite or Questran) or colestipol (Colestid); oral contraceptives that contain higher concentrations of estrogen, specifically: Ovral, Ogestrel, Demulen, Ovon, and Ortho-Novum; and the antidepressants trimipramine (Surmontil) and venlafaxine (Effexor).
    • Patients on estrogen taken for menopause because it may lower blood pressure
    • Patients not willing to stop their glaucoma medication temporarily
    • Patients with dry eye disease

      2) Control Patients

      • Age less than 18 years or greater than 80 years.

        • Patients with high intraocular pressure (> 21 mmHg).
        • Patients who have had any type of glaucoma surgery in the past.
        • Non-glaucomatous optic neuropathy.
        • Intraocular surgery within the last 3 months.
        • Patients with uveitis
        • Ocular abnormalities preventing measurement of intraocular pressure by applanation
        • Patients on medication to treat high blood pressure will not be included in the study.
        • Patients with hyperthyroidism
        • Patients on medication that may raise blood pressure: i.e. systemic or topical steroids taken for 3 or more years for other chronic conditions; cholesterol lowering medications, specifically cholestyramine (Prevalite or Questran) or colestipol (Colestid); oral contraceptives that contain higher concentrations of estrogen, specifically: Ovral, Ogestrel, Demulen, Ovon, and Ortho-Novum; and the antidepressants trimipramine (Surmontil) and venlafaxine (Effexor).
        • Patients on estrogen taken for menopause because it may lower blood pressure
        • Patients with dry eye disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01912599


Locations
Layout table for location information
United States, North Carolina
UNC Kittner Eye Center
Chapel Hill, North Carolina, United States, 27599-7040
Sponsors and Collaborators
University of North Carolina, Chapel Hill
Sensimed AG
Investigators
Layout table for investigator information
Principal Investigator: Jean-Claude Mwanza, MD, PhD University of North Carolina, Chapel Hill

Layout table for additonal information
Responsible Party: University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier: NCT01912599     History of Changes
Other Study ID Numbers: 12-2514
First Posted: July 31, 2013    Key Record Dates
Results First Posted: June 17, 2016
Last Update Posted: June 17, 2016
Last Verified: September 2014
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University of North Carolina, Chapel Hill:
Glaucoma
Intraocular Pressure
Blood Pressure
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma
Low Tension Glaucoma
Ocular Hypertension
Eye Diseases
Optic Nerve Diseases